Karl S Peggs

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
    Karl S Peggs
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:809-24. 2005
  2. ncbi request reprint Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans
    K S Peggs
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytotherapy 8:427-36. 2006
  3. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
  4. pmc Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
    Sergio A Quezada
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 205:2125-38. 2008
  5. ncbi request reprint Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative
    Karl S Peggs
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 12:192-9. 2007
  6. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
  7. pmc Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 207:637-50. 2010
  8. pmc Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Immunol Rev 241:104-18. 2011
  9. doi request reprint Epitope landscape in breast and colorectal cancer
    Neil H Segal
    Department of Medicine, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:889-92. 2008
  10. ncbi request reprint Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 18:206-13. 2006

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
    Karl S Peggs
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Br J Haematol 130:809-24. 2005
    ....
  2. ncbi request reprint Reconstitution of adaptive and innate immunity following allogeneic hematopoietic stem cell transplantation in humans
    K S Peggs
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cytotherapy 8:427-36. 2006
    ..This review summarizes more recent data on immune reconstitution following allogeneic transplantation in humans...
  3. pmc Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 206:1717-25. 2009
    ....
  4. pmc Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma
    Sergio A Quezada
    Howard Hughes Medical Institute and the Ludwig Center for Cancer Immunotherapy, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 205:2125-38. 2008
    ..The data demonstrate a dissociation between measurable systemic responses and tumor rejection during CD25-directed T reg cell depletion, and suggest an alternative, clinically applicable strategy for the treatment of established tumors...
  5. ncbi request reprint Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative
    Karl S Peggs
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, 1275 York Avenue, New York, NY 10021, USA
    Cancer Cell 12:192-9. 2007
    ..We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoints...
  6. pmc CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
    Sergio A Quezada
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Clin Invest 116:1935-45. 2006
    ....
  7. pmc Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Exp Med 207:637-50. 2010
    ....
  8. pmc Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
    Sergio A Quezada
    Ludwig Center for Cancer Immunotherapy, Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Immunol Rev 241:104-18. 2011
    ..Finally, we also discuss work associated to the manipulation of the immune response to tumors and its impact on the infiltration, accumulation, and function of tumor-reactive lymphocytes within the tumor microenvironment...
  9. doi request reprint Epitope landscape in breast and colorectal cancer
    Neil H Segal
    Department of Medicine, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 68:889-92. 2008
    ..These data suggest that, with appropriate manipulation of the immune system, tumor cell destruction in situ may provide a polyvalent tumor vaccine without a requirement for knowledge of the targeted antigens...
  10. ncbi request reprint Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    Karl S Peggs
    Howard Hughes Medical Institute, Department of Immunology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Curr Opin Immunol 18:206-13. 2006
    ..Finding ways to dissociate antitumor activity from adverse immune events should enable actualization of their therapeutic potential in the coming years...
  11. ncbi request reprint Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses
    Karl S Peggs
    Department of Haematology, University College Hospital, 98 Chenies Mews, London, WC1E 6HX, United Kingdom
    Blood 103:1548-56. 2004
    ....
  12. ncbi request reprint Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation
    Karl S Peggs
    Department of Haematology, Royal Free and University College London, UK
    Lancet 365:1934-41. 2005
    ..Therefore, we aimed to assess the graft-versus-tumour effect of reduced-intensity allogeneic transplantation...
  13. ncbi request reprint Adoptive cellular therapy: a therapeutic reality?
    Karl S Peggs
    Department of Haematology, University College Hospital, London, UK
    Hematology 7:127-36. 2002
    ..This review summarizes these developments and highlights some of the issues that remain to be resolved...
  14. doi request reprint Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
    Karl S Peggs
    Department of Haematology, UCL Cancer Institute, University College London, London, UK
    Immunol Rev 224:141-65. 2008
    ....
  15. ncbi request reprint Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications
    Emma C Morris
    Department of Haematology, University College Hospital, 98 Chenies Mews, London WC1E 6HX, UK
    Blood 102:404-6. 2003
    ..Total lymphocyte counts were significantly lower in the RIT group persisting beyond 6 months after transplantation (P =.005), and median absolute CD4 counts higher than 200 x 106/L were delayed until 9 months after transplantation...
  16. ncbi request reprint Reduced intensity transplantation: where are we now?
    Stephen Mackinnon
    Royal Free and University College London, London, UK
    Hematol J 5:S34-8. 2004
  17. ncbi request reprint Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical School, London, United Kingdom
    Hum Immunol 65:550-7. 2004
    ..This simple in vitro methodology should allow widespread application of adoptive transfer of virus-specific T cells...
  18. ncbi request reprint Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes
    Karl S Peggs
    Department of Haematology, Royal Free and University College, London, UK
    Br J Haematol 139:70-80. 2007
    ....
  19. ncbi request reprint High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma
    Adrian J C Bloor
    Department of Haematology, Royal Free and University College London School of Medicine, London, United Kingdom
    Biol Blood Marrow Transplant 14:50-8. 2008
    ..These data support the existence of a clinically significant graft-versus-tumor effect in indolent NHL and suggest that this is an effective treatment for progressive disease after allogeneic SCT...
  20. ncbi request reprint Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, United Kingdom
    Biol Blood Marrow Transplant 9:257-65. 2003
    ..Attempts to hasten immune reconstitution and to focus and amplify appropriate components of allogeneic T-cell responses will be required to increase complete remission rates and response durations...
  21. ncbi request reprint CD34+ cell dose and the occurrence of GVHD in the presence of in vivo T-cell depletion
    Kirsty J Thomson
    Blood 103:743. 2004
  22. ncbi request reprint Role of allogeneic stem cell transplantation in multiple myeloma
    Kirsty J Thomson
    Department of Hematology, University College London Hospitals, London, UK
    Expert Rev Anticancer Ther 5:455-64. 2005
    ..This review aims to examine the current position of allogeneic transplantation in the management of myeloma...
  23. ncbi request reprint Reduced intensity conditioning and allogeneic stem-cell transplantation: determining its role in multiple myeloma
    Karl S Peggs
    J Clin Oncol 20:4268; author reply 4268-9. 2002
  24. ncbi request reprint Assessing diversity: immune reconstitution and T-cell receptor BV spectratype analysis following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London, London, UK
    Br J Haematol 120:154-65. 2003
    ..The novel and objective diversity scoring system described appears better able to document changes in spectratype patterns than previously described techniques and should aid the standardization of reporting...
  25. ncbi request reprint Development and clinical application of a fully controlled quantitative PCR assay for cell-free cytomegalovirus in human plasma
    Wolfgang Preiser
    Department of Virology, Royal Free and University College School of Medicine and University College London Hospitals NHS Trust UCLH, Windeyer Building, 46 Cleveland Street, London W1P 6DB, UK
    J Clin Virol 26:49-59. 2003
    ..The quantification of HCMV genome is clinically useful for the diagnosis of HCMV disease, for the virological surveillance of high-risk patients and for monitoring antiviral therapy...
  26. ncbi request reprint Reconstitution of T-cell repertoire after autologous stem cell transplantation: influence of CD34 selection and cytomegalovirus infection
    Karl S Peggs
    Department of Haematology, University College London, London, United Kingdom
    Biol Blood Marrow Transplant 9:198-205. 2003
    ....
  27. ncbi request reprint Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines
    Karl S Peggs
    Royal Free and University College London Medical School, London, UK
    Lancet 362:1375-7. 2003
    ..Our findings indicate that application of CMV-specific cell lines is both feasible and effective in a clinical environment...
  28. ncbi request reprint Immune reconstitution following haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Br J Haematol 124:407-20. 2004
  29. ncbi request reprint Cytomegalovirus: the role of CMV post-haematopoietic stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College Hospital, London WC1E 6HX, UK
    Int J Biochem Cell Biol 36:695-701. 2004
    ..Efforts have therefore focused on molecular diagnostic surveillance protocols that allow earlier intervention, and the development of adoptive immunotherapeutic strategies to hasten host immune reconstruction...
  30. ncbi request reprint Immune reconstitution following stem cell transplantation
    Karl S Peggs
    Department of Haematology, University College London Hospitals, London, UK
    Leuk Lymphoma 45:1093-101. 2004
    ..This review focuses mainly on recent advances in the understanding of immune reconstitution in the allogeneic setting...
  31. ncbi request reprint Cytomegalovirus following stem cell transplantation: from pharmacologic to immunologic therapy
    Karl S Peggs
    Department of Hematology, Royal Free and University College London Medical School, 98 Chenies Mews, London, WC1E 6HX, UK
    Expert Rev Anti Infect Ther 2:559-73. 2004
    ..Efforts have therefore focused on molecular diagnostic surveillance protocols that allow earlier intervention and the development of adoptive immunotherapeutic strategies to hasten host immune reconstitution...
  32. ncbi request reprint The role of allogeneic transplantation in non-Hodgkin's lymphoma
    Karl S Peggs
    Department of Haematology, Royal Free and University College London Medical Schools, London, UK
    Br J Haematol 128:153-68. 2005
    ....
  33. ncbi request reprint Outcome of major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation may be influenced by conditioning regimen
    Karl S Peggs
    Blood 99:4642-3; author reply 4643-4. 2002